Brief Report
Volume 08:05, 2025

Journal of Clinical Neurology and Neurosurgery

ISSN: 2684-6012

Open Access

Optimizing Traumatic ICH Diagnosis, Prognosis, Management

Priya K. Nair*

Department of Neurosurgery, University of Melbourne, Melbourne, Australia

Introduction

This systematic review explores the diagnostic and prognostic value of non-enhanced computed tomography (NECT) in patients suffering from traumatic brain injury (TBI) with intracranial hemorrhage. It highlights how NECT findings, beyond just identifying the hemorrhage, can predict patient outcomes and guide management strategies by revealing specific injury patterns and their severity[1].

This study introduces a new, simple scoring system designed to predict early neurological deterioration in patients with mild traumatic intracranial hemorrhage. The score aims to help clinicians quickly identify high-risk individuals who may benefit from closer monitoring or early intervention, potentially improving patient outcomes[2].

This systematic review and meta-analysis examines the management strategies for both spontaneous and traumatic intracranial hemorrhage in patients who are on direct oral anticoagulants. It synthesizes evidence to guide treatment decisions, focusing on how these agents influence bleeding risk and what interventions are most effective[3].

This research identifies clinical predictors for outcomes and prognosis in patients experiencing traumatic intracranial hemorrhage while on direct oral anticoagulants. Understanding these predictors is crucial for risk stratification and tailoring individualized treatment plans to improve survival and reduce morbidity in this vulnerable population[4].

This article specifically addresses traumatic intracranial hemorrhage in geriatric patients, a population with unique challenges due to age-related physiological changes, comorbidities, and often polypharmacy, including anticoagulants. It sheds light on the specific diagnostic and management considerations necessary for older individuals to optimize their outcomes[5].

This systematic review investigates the role of antithrombotic agents in patients with traumatic intracranial hemorrhage. It summarizes current evidence on how these medications impact bleeding progression and clinical outcomes, guiding clinicians in managing patients who are on such agents at the time of injury[6].

This paper introduces the Traumatic Intracranial Hemorrhage and Anticoagulation (TIHAA) Score, a novel tool designed to predict in-hospital mortality in patients presenting with traumatic intracranial hemorrhage while on anticoagulants. This score offers a practical method for risk assessment and improving patient care in the emergency setting[7].

This study focuses on the management of traumatic intracranial hemorrhage in older patients who are receiving antiplatelet agents. Given the increased risk of bleeding and complications in this demographic, the article provides insights into effective strategies for managing these complex cases, emphasizing the balance between preventing thrombosis and controlling hemorrhage[8].

This research identifies specific risk factors for the worsening of traumatic intracranial hemorrhage in patients undergoing antiplatelet therapy. Understanding these factors is critical for proactive management and intervention, aiming to mitigate the progression of bleeding and improve neurological outcomes for this high-risk group[9].

This article explores the complex interplay of traumatic intracranial hemorrhage and anticoagulation with unfractionated heparin in patients experiencing acute coronary syndrome who undergo percutaneous coronary intervention. It addresses the delicate balance required when managing both severe bleeding risk and the need for anticoagulation in critical cardiac patients[10].

Description

Traumatic intracranial hemorrhage presents a complex clinical challenge, with ongoing research aiming to refine diagnostic, prognostic, and management strategies. A key diagnostic tool explored is non-enhanced computed tomography (NECT), which not only identifies hemorrhage but also provides crucial predictive insights into patient outcomes based on specific injury patterns and severity in traumatic brain injury (TBI) [1]. Early identification of risk is paramount, leading to the development of novel scoring systems. For instance, a new simple score has been introduced to predict early neurological deterioration in patients with mild traumatic intracranial hemorrhage, enabling clinicians to quickly pinpoint high-risk individuals for closer monitoring or intervention [2].

A substantial area of focus involves the intricate management of intracranial hemorrhage in patients who are already on antithrombotic agents. Systematic reviews and meta-analyses provide comprehensive guidance on managing both spontaneous and traumatic intracranial hemorrhage in those receiving direct oral anticoagulants (DOACs), synthesizing evidence on how these agents influence bleeding risk and what interventions are most effective [3]. Similarly, the broader role of antithrombotic agents in traumatic intracranial hemorrhage has been systematically reviewed, summarizing current evidence on their impact on bleeding progression and clinical outcomes to inform clinical management [6]. Understanding the interplay between these medications and hemorrhage is vital for patient care.

Beyond general management, studies delve into specific clinical predictors and

risk factors. Research has identified clinical predictors for outcomes and prognosis in patients experiencing traumatic intracranial hemorrhage while on DOACs, emphasizing the importance of this knowledge for risk stratification and individualized treatment to improve survival and reduce morbidity in this vulnerable group [4]. For patients on antiplatelet therapy, specific risk factors for the worsening of traumatic intracranial hemorrhage have been identified. Recognizing these factors is critical for proactive management and intervention, aiming to mitigate bleeding progression and enhance neurological outcomes for high-risk individuals [9].

Geriatric patients represent a particularly challenging demographic in the context of traumatic intracranial hemorrhage. This population often presents with unique considerations due to age-related physiological changes, multiple comorbidities, and frequently, polypharmacy that includes anticoagulants [5]. Dedicated studies highlight the specific diagnostic and management approaches necessary to optimize outcomes for older individuals [5]. Furthermore, the management of traumatic intracranial hemorrhage in older patients receiving antiplatelet agents is a distinct concern. Given their increased risk of bleeding and complications, effective strategies must balance preventing thrombosis and controlling hemorrhage in these complex cases [8].

Finally, tools for predicting mortality and managing highly specific scenarios contribute to comprehensive care. The Traumatic Intracranial Hemorrhage and Anticoagulation (TIHAA) Score, for example, is a novel tool designed to predict in-hospital mortality in patients with traumatic intracranial hemorrhage who are on anticoagulants, offering a practical method for emergency risk assessment and patient care improvement [7]. Additionally, specialized research addresses the complex intersection of traumatic intracranial hemorrhage and anticoagulation with unfractionated heparin in patients undergoing percutaneous coronary intervention for acute coronary syndrome. This highlights the delicate balance required when managing severe bleeding risk alongside the necessity for anticoagulation in critically ill cardiac patients [10].

Conclusion

The available research focuses on traumatic intracranial hemorrhage, highlighting diagnostic and prognostic tools, particularly non-enhanced computed tomography (NECT), which can predict patient outcomes by revealing injury patterns and severity [1]. Significant effort is dedicated to developing scoring systems to identify high-risk individuals and predict early neurological deterioration in mild cases [2], or to forecast in-hospital mortality for those on anticoagulants [7]. A major theme involves managing intracranial hemorrhage in patients receiving various antithrombotic agents, including direct oral anticoagulants [3, 4], antiplatelet agents [6, 8, 9], and unfractionated heparin [10]. Researchers explore how these medications affect bleeding progression and clinical outcomes, aiming to guide treatment decisions and balance bleeding risks against the need for anticoagulation [3, 6, 10]. Specific attention is given to the unique challenges faced by geriatric patients, who often present with comorbidities and polypharmacy, necessitating tailored diagnostic and management strategies [5, 8]. Studies also identify clinical predictors for outcomes and prognosis in these vulnerable populations, aiming to improve risk stratification, mitigate bleeding progression, and enhance overall survival and neurological outcomes [4, 9]. This body of work underscores the complexity of traumatic intracranial hemorrhage and the ongoing need for refined diagnostic, prognostic, and management approaches across diverse patient groups.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Xiao Lin, Dong Liu, Bin Ma. “Prognostic Value of Non-Enhanced Computed Tomography in Traumatic Brain Injury with Intracranial Hemorrhage: A Systematic Review.” *World Neurosurgery* 184 (2024):e1-e12.

2. Yue Wu, Jing Yan, Chun Huang. “A New Simple Score for Predicting Early Neurological Deterioration in Mild Traumatic Intracranial Hemorrhage.” *World Neurosurgery* 180 (2023):e799-e806.

3. Si Chen, Alessandro Zappala, Yang Pan. “Management of spontaneous and traumatic intracranial hemorrhage in patients on direct oral anticoagulants: a systematic review and meta-analysis.” *BMC Medicine* 21 (2023):217.

4. Shijun Liu, Shaohong Jin, Baoxi Huang. “Clinical Predictors for Outcomes and Prognosis of Traumatic Intracranial Hemorrhage in Patients on Direct Oral Anticoagulants.” *Frontiers in Neurology* 13 (2022):920807.

5. Erik Van Leer, Freek J A Meijer, Ewoud H C Van Dijk. “Traumatic intracranial hemorrhage in geriatric patients.” *European Journal of Trauma and Emergency Surgery* 48 (2022):4007-4015.

6. Shubham Sharma, Aman Bains, Sakshi Chibber. “Role of Antithrombotic Agents in Traumatic Intracranial Hemorrhage: A Systematic Review.” *World Neurosurgery* 179 (2023):e62-e67.

7. Dina Shamloul, Ahmed Salih, Ines Osorno. “The *Traumatic Intracranial Hemorrhage and Anticoagulation* (TIHAA) Score: A novel score to predict in-hospital mortality in patients presenting with traumatic intracranial hemorrhage on anticoagulants.” World Neurosurgery 149 (2021):e35-e40.

8. Hidenori Nishimura, Masaki Ohgami, Akinori Oshima. “Management of traumatic intracranial hemorrhage in older patients receiving antiplatelet agents.” *Journal of Neurosurgical Sciences* 64 (2020):578-583.

9. Akinori Oshima, Hidenori Nishimura, Masaki Ohgami. “Risk Factors for Worsening of Traumatic Intracranial Hemorrhage in Patients on Antiplatelet Therapy.” *World Neurosurgery* 133 (2020):e376-e381.

10. Lukas Pielsticker, Christopher Bleyer, Helene Gries. “Traumatic intracranial hemorrhage and anticoagulation with unfractionated heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention.” *BMC Cardiovascular Disorders* 20 (2020):425.

How to cite this article: Nair, Priya K.. ”Optimizing Traumatic ICH Diagnosis, Prognosis, Management.” *J Clin Neurol Neurosurg* 08 (2025):314.

Address for Correspondence: Priya, K. Nair, Department of Neurosurgery, University of Melbourne, Melbourne, Australia, E-mail: priya.nair@unimelb.edu.au

Received: 02-Oct-2025, Manuscript No. jcnn-25-173646; **Editor assigned:** 06-Oct-2025, PreQC No. P-173646; **Reviewed:** 20-Oct-2025, QC No. Q-173646; **Revised:** 23-Oct-2025, Manuscript No. R-173646; **Published:** 30-Oct-2025, DOI: 10.37421/2684-6012.2025.8.314